Introduction
Progressive supranuclear palsy (PSP) or Steele-Richardson-Olszewski syndrome is a progressive neurodegenerative disorder characterized by progressive gait disturbance (with poor balance and early falls) and a supranuclear gaze palsy (typically downward gaze)[
1‐
4]. Other features may include axial and limb rigidity, motor eyelid disorders, pseudobulbar signs (dysarthria and dysphagia), and frontal/subcortical dementia [
1‐
3]. Patients typically present in their 5th–7th decade [
5,
6]. The mean onset age is 63 years and the mean survival is 6–9 years [
2,
3,
5,
6]. The incidence of PSP is estimated to be between 1.4 and 5.3 per 100,000 [
2,
3]. Neuropathologically, PSP is associated with the deposition of hyperphosphorylated tau as neurofibrillary tangles, neuropil threads, and fibrillary gliosis in the pallidum, subthalamic nucleus, red nucleus, striatum, substantia nigra, pontine tegmentum, oculomotor nucleus, medulla, and dentate nucleus [
3,
7,
8].
Corticobasal degeneration (CBD) is a progressive neurodegenerative disease characterized by progressive asymmetrical rigidity and apraxia [
9,
10•,
11]. Symptoms and presentation vary and patients may experience dystonia, myoclonus, tremor, alien limb phenomenon, motor speech disorders, eye movement disturbance, cortical dementia, and cortical sensory loss [
10•,
12‐
14]. Patients typically present in their 6th or 7th decades (mean age of onset 64) and mean survival is 6 to 7 years [
11,
15‐
17]. The incidence of CBD is estimated to be between 0.62 and 0.92 per 100,000 with a prevalence of 4.9–7.3 per 100,000 [
9]. CBD is associated with accumulation of aggregates containing the four-repeat isoforms of tau [
12,
13,
18]. Neuropathologically, CBD is defined by asymmetrical parietal and frontal cortical degeneration, with neurofilament protein-positive ballooned neurons and tau-positive astrocytic plaques and coiled bodies in oligodendrocytes [
11]. However, the clinical syndrome of CBD is increasingly reported with other underlying pathologies such as Alzheimer’s disease (AD), frontotemporal lobar degeneration, PSP, dementia with Lewy bodies, and Creutzfeldt-Jakob disease; therefore, patients are often described as having a corticobasal syndrome (CBS) until a definitive diagnosis of CBD can be made [
19].
The diagnoses of PSP and CBD are difficult due to the lack of specific biomarkers and is further complicated by the fact that many of the clinical features of PSP and CBD overlap with each other and with other neurodegenerative diseases, including multiple system atrophy (MSA) and disorders within the frontotemporal dementia spectrum (behavioral variant FTD—bvFTD and primary progressive aphasia—PPA) [
12,
13,
15,
18].
Disease-modifying therapies for PSP and CBD have targeted tau pathology. Davunetide is thought to decrease tau phosphorylation by promoting microtubule stability; however, in a randomized double-blind placebo-controlled trial in 313 patients with PSP, although well tolerated, davunetide was ineffective, showing no improvement in the progressive supranuclear palsy rating scale or Schwab and England activities of daily living scale [
20]. Glycogen synthase kinase-3 (GSK-3) is a kinase believed to play a role in the hyperphosphorylation of the tau protein. However, in a randomized, double-blind, placebo-controlled trial of 146 patients with PSP Tideglusib, a GSK-3 inhibitor, although well tolerated, was not shown to be clinically effective [
21••]. Lithium has also been shown to regulate GSK-3; however, in a randomized, single-blind, placebo-controlled trial of 71 patients with AD, lithium was not shown to have any treatment effect on GSK-3 activity and did not support the notion that it reduced tau hyperphosphorylation [
22]. Riluzole is considered neuroprotective and has been shown to block glutamatergic neurotransmission in the central nervous system and is well tolerated and prolongs survival in patients with amyotrophic lateral sclerosis; however, in a randomized, double-blind, placebo-controlled trial of patients with PSP, riluzole was not shown to improve survival in PSP and similarly did not improve survival in patients with MSA [
23,
24••,
25,
26]. Lisuride was also shown to have no significant effect in the treatment of PSP [
6].
In the absence of approved pharmacological treatments for PSP and CBD, management should be based on relieving symptoms and assisting patients with their activities of daily living [
3,
9,
27]. Advanced care planning and non-pharmacological supportive therapies remain paramount in the management of PSP and CBD. Most patients will be trialed on L-DOPA and amantadine, although there is limited evidence for benefit some patients may experience modest improvement in Parkinsonism [
15,
32,
61]. Botulinum toxin is helpful in reducing dystonia and in managing sialorrhoea and is particularly useful for eyelid dysmotility [
23,
30,
31,
57,
60‐
63].
Advanced care planning should be addressed at the earliest possible opportunity, and ideally, when the patient is able (and legally competent) to communicate their wishes about their treatment preferences. Early input by the palliative care team is advised to explore the patients’ feelings about resuscitation status, ceilings of care, and artificial feeding using radiologically inserted gastrostomy (RIG) and percutaneous endoscopic gastrostomy (PEG). Where artificial feeding tubes are sited, decisions should me made about criteria for future withdrawal. Review by psychologists or psychiatrists may be helpful where patients exhibit challenging behaviors. Patient and caregiver education is important, and patients should be given plenty of information about relevant support groups. In some circumstances, patients may need a social worker who can provide advice about support from social services.
Compliance with Ethical Standards